Logo
Logo

About Eszopiclone API

Product
  • Therapeutic CategoryCentral Nervous System (CNS)

  • CAS Number

    138729-47-2

  • API Technology

    Synthetic

  • Dose Form

    Oral Solid/Tablets

  • Dr Reddy's Development Status

    Available

  • Available Regulatory Filing

    USDMF

Mechanism of Action

The precise mechanism of action of eszopiclone as a hypnotic is unknown, but its effect is believed to result from its interaction with GABA-receptor complexes at binding domains located close to or allosterically coupled to benzodiazepine receptors. Eszopiclone is a nonbenzodiazepine hypnotic that is a pyrrolopyrazine derivative of the cyclopyrrolone class with a chemical structure unrelated to pyrazolopyrimidines, imidazopyridines, benzodiazepines, barbiturates, or other drugs with known hypnotic properties.

Indication

LUNESTA is indicated for the treatment of insomnia. LUNESTA has been shown to decrease sleep latency and improve sleep maintenance

Related APIs

Apremilast (Amorphous & Form B)

Central Nervous System (CNS)

arrow

Atomoxetine Hydrochloride

Central Nervous System (CNS)

arrow

Benztropine Mesylate

Central Nervous System (CNS)

arrow

Dimethyl Fumarate

Central Nervous System (CNS)

arrow

Donepezil HCl

Central Nervous System (CNS)

arrow

Edaravone

Central Nervous System (CNS)

arrow

Eslicarbazepine Acetate

Central Nervous System (CNS)

arrow

Eszopiclone

Central Nervous System (CNS)

arrow

Levetiracetam

Central Nervous System (CNS)

arrow

Lumateperone Tosylate

Central Nervous System (CNS)

arrow

Lurasidone Hydrochloride

Central Nervous System (CNS)

arrow

Memantine Hydrochloride

Central Nervous System (CNS)

arrow

Pregabalin

Central Nervous System (CNS)

arrow

Quetiapine Fumarate

Central Nervous System (CNS)

arrow

Rimegepant

Central Nervous System (CNS)

arrow

Risperidone

Central Nervous System (CNS)

arrow

Rivastigmine Hydrogen Tartrate

Central Nervous System (CNS)

arrow

Ropinirole Hydrochloride

Central Nervous System (CNS)

arrow

Siponimod

Central Nervous System (CNS)

arrow

Sugammadex Sodium

Central Nervous System (CNS)

arrow

Tizanidine Hydrochloride

Central Nervous System (CNS)

arrow

Xanomeline

Central Nervous System (CNS)

arrow

Ziprasidone Hydrochloride

Central Nervous System (CNS)

arrow

Request for Quotation

Get in touch with us by filling out the form below. Our team will reach out to you shortly!

Phone

Related Resources

Indian healthcare reform offers thriving pharmaceutical market opportunities: Interview with Deepak Sapra

Indian healthcare reform offers thriving pharmaceutical market opportunities: Interview with Deepak Sapra

August 25, 2020Global Pharma Insights spoke to Deepak Sapra (below), CEO of Active Pharmaceutical Ingredients and Services at Dr. Reddy's Laboratories for his perspective on the current state of the Indian healthcare and pharmaceuticals sector and how it is providing opportunities for both domestic and multinational drugmakers and healthcare providers despite the challenges of the ongoing coronavirus pandemic.To read the interview click here
Disclaimer: Products under patent(s) are offered only for R&D purposes U/S 107A of the Patent Act (Bolar Exemption) and not for commercial sale.